BioPharmSignal logoBioPharmSignal

Biotech News

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Jaguar Health (JAGX)Jaguar HealthConference / presentation

Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern Participant Registration & Access Link: Click Here Replay Instructions for Webcast Replay of the

Open original release

Related news

JAGXJaguar Health2026-05-20 13:00 EST

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

JAGXJaguar Health2026-05-20 20:40 EST

Jaguar Health Reports First Quarter 2026 Financials

VIRXViracta Therapeutics2024-09-05 15:32 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-05-28 14:00 EST

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

JAGXJaguar Health2026-05-27 13:00 EST

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGXJaguar Health2026-05-20 20:40 EST

Jaguar Health Reports First Quarter 2026 Financials

JAGXJaguar Health2026-05-20 13:00 EST

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

JAGXJaguar Health2026-05-19 13:00 EST

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

Stock data

Close
1.00 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California